Last week's approval of Biogen's Aduhelm (aducanumab) for Alzheimer's disease is arguably the most controversial in the FDA's history.
Exactly how Aduhelm will be used by physicians remains up for debate. Many are sceptical of the clinical data and don't think the drug should have been approved, at least not with such a broad label.
Neurologists are also aware, nevertheless, that they will be under enormous pressure from patients and their families to prescribe Aduhelm given the lack of alternative disease-modifying therapies for Alzheimer's.
Join FirstWord Pharma editors Michael Flanagan and Simon King later today (16 June, 10am ET / 3pm GMT) for a live discussion about the approval, its implications and results from our new survey of 50 US neurologists, which sheds further light on how Aduhelm will be used.
Register here for this live event, which is exclusive to FirstWord Pharma PLUS subscribers.
To read more Physician Views articles, click here.